Seizure Detection Performance evaluation of the Model 106 VNS Therapy® System up to 26 months [clinicaltrials_resource:57f1b774f247176473e9b908e58a3b66]
The primary study objective is to evaluate the Model 106 VNS Therapy® System cardiac-based seizure detection and Automatic Magnet Mode (AMM) stimulation in epilepsy patients.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Seizure Detection Performance evaluation of the Model 106 VNS Therapy® System up to 26 months [clinicaltrials_resource:57f1b774f247176473e9b908e58a3b66]
The primary study objective is to evaluate the Model 106 VNS Therapy® System cardiac-based seizure detection and Automatic Magnet Mode (AMM) stimulation in epilepsy patients.
Bio2RDF identifier
57f1b774f247176473e9b908e58a3b66
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:57f1b774f247176473e9b908e58a3b66
measure [clinicaltrials_vocabulary:measure]
Seizure Detection Performance evaluation of the Model 106 VNS Therapy® System
time frame [clinicaltrials_vocabulary:time-frame]
up to 26 months
description
The primary study objective is ...... mulation in epilepsy patients.
identifier
clinicaltrials_resource:57f1b774f247176473e9b908e58a3b66
title
Seizure Detection Performance ...... herapy® System up to 26 months
@en
type
label
Seizure Detection Performance ...... 1b774f247176473e9b908e58a3b66]
@en